At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma
In Brief
A Phase 1 clinical trial evaluating Arm 1: IL13Ra2-specific CAR Tcm cells, Arm 2: IL13Ra2-specific CAR Tcm cells, and 7 other interventions for Recurrent Glioblastoma and 7 related conditions. Active but no longer recruiting, targeting 65 participants across 1 site.
Detailed Summary
This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory). A T cell is a type of immune cell that can recognize and kill abnormal cells in the body. T cells are taken from the patient's blood and a modified gene is placed into them in the laboratory and this may help them recognize and kill glioma cells. Genetically modified T-cells may also help the body build an immune response against the tumor cells.
Study Details
Timeline
Interventions
Given via intratumoral catheter
Given via intratumoral/intracavitary catheter
Given via intraventricular catheter
Given via intratumoral or intracavitary, and via intraventricular catheter
Given via intratumoral or intracavitary, and via intraventricular catheter
Correlative studies
Correlative studies
Correlative studies
Ancillary studies